Systemic bio™ opens state-of-the-art laboratory for bioprinted organ-on-a-chip r&d, production to accelerate drug discovery & development

Houston, april 05, 2023 (globe newswire) -- today, systemic bio™, a 3d systems (nyse:ddd) company, announced the opening of its new headquarters for hydrogel scaffold manufacturing and organ-on-a-chip r&d to facilitate its mission to accelerate drug discovery and development. this state-of-the-art facility contains a cleanroom for bioprinted hydrogel production and is located in the tmc innovation factory labs on the texas medical center campus in houston. from this location, systemic bio's engineers and scientists will continue the development and production of the company's proprietary h-vios™ (human vascularized integrated organ systems) organ-on-a-chip platform.
DDD Ratings Summary
DDD Quant Ranking